GLP1R and obesity due to melanocortin 4 receptor deficiency: Retatrutide represents a promising advancement in pharmacologic therapy for obesity, offering potential for greater weight reduction than currently available GLP-1 RAs, although long-term safety and real-world effectiveness remain under investigation.